What Happens If Polymyalgia Rheumatica Is Not Treated?

Untreated polymyalgia rheumatica (PMR) leaves the body locked in a state of chronic inflammation that causes far more than muscle pain. The immediate toll is severe enough on its own: most people with active PMR struggle with basic tasks like getting out of bed, dressing, and using the toilet. But the longer-term consequences are what make ignoring PMR genuinely dangerous. Unchecked inflammation accelerates bone loss, raises the odds of hidden vascular disease, and drives a cascade of physical decline that can be difficult to reverse.

The Daily Reality of Untreated PMR

PMR primarily attacks the soft tissues around the shoulders, hips, and knees, causing deep aching pain and profound stiffness that is worst in the morning. This is not ordinary muscle soreness that stretches out after a few minutes. People with active disease often describe needing thirty minutes to an hour just to loosen up enough to move normally, and for some the stiffness never fully clears. The result is a dramatic restriction in range of motion that makes routine life difficult. Research into the functional impact of PMR has found that the majority of people with active disease report difficulty performing simple activities of daily living, from getting out of a chair to reaching overhead to dress themselves.¹

Without treatment, this disability persists for months or years. PMR is not a condition that reliably burns itself out. While some case series have observed eventual changes in disease pattern, only a small minority of patients followed without corticosteroid treatment stayed “true to form” with straightforward PMR that resolved on its own. In one observational cohort, just 13% of patients managed without steroids retained a pure PMR diagnosis; the vast majority went on to develop joint inflammation in other areas.² That finding underscores how rarely PMR simply fades away if you wait it out.

What Chronic Inflammation Does to Your Bones

PMR drives an intense inflammatory response. Before any treatment begins, nearly all patients show elevated markers of inflammation. In one prospective study, C-reactive protein was elevated in roughly 99% of patients, the erythrocyte sedimentation rate in about 92%, and interleukin-6 (a key inflammatory signaling molecule) in about 93%.³ Separate research confirmed that interleukin-6 was significantly elevated in all untreated PMR patients tested.⁴

This matters beyond the pain it causes, because systemic inflammation directly attacks bone. Studies of untreated PMR patients have found that bone resorption markers are significantly increased while bone formation markers are significantly decreased, meaning the skeleton is being broken down faster than it can rebuild. The degree of bone breakdown correlates with disease activity: the more inflamed you are, the faster you lose bone.⁵ A second study confirmed this uncoupling of bone turnover in untreated patients, concluding that the disease process alone could lead to a decrease in skeletal mass over time.⁶

This is an especially cruel irony of PMR. The disease strikes people over 50, almost always over 65, a population already at risk for osteoporosis. Layering aggressive inflammatory bone loss on top of age-related thinning pushes people toward fractures. And because untreated PMR also causes immobility and muscle weakness (more on that below), the fall risk goes up at the same time the bones are getting weaker. Treatment with corticosteroids carries its own bone-thinning risks, which is well known, but the evidence suggests that bringing inflammation under control actually helps bone turnover normalize, making treatment the lesser of two evils for skeletal health.

The Hidden Danger of Giant Cell Arteritis

PMR and giant cell arteritis (GCA) are closely related conditions that frequently overlap. GCA involves inflammation of medium and large arteries, particularly branches of the aorta that supply blood to the head and eyes. The connection between the two diseases is tight enough that researchers debate whether they represent separate conditions or different points on a single spectrum of inflammatory disease.⁷

What makes this relevant to untreated PMR is that roughly one in four newly diagnosed PMR patients already has subclinical GCA, meaning the arterial inflammation is present but has not yet produced obvious symptoms like headache, jaw pain, or scalp tenderness. Estimates put the prevalence of subclinical GCA at about 23 to 29% in PMR patients, depending on the imaging method used to look for it.⁷ Routine screening for GCA in PMR patients is not yet standard practice, so many of these cases go undetected until symptoms emerge.

Unrecognized and untreated GCA can cause permanent vision loss. The most feared complication is arteritic ischemic optic neuropathy, where inflammation blocks blood flow to the optic nerve. In a large study of GCA patients, this specific complication occurred in about 7% of cases and accounted for 85% of all permanent vision loss from GCA.⁸ Vision loss from GCA is typically sudden, painless, and irreversible. It can affect one eye or both, and when it strikes the second eye it often does so within days to weeks of the first. This is the single strongest argument against leaving PMR untreated: if GCA is smoldering alongside it and nobody catches it, the first sign could be waking up unable to see out of one eye.

Does PMR Itself Damage Blood Vessels?

Beyond the GCA overlap, there has been longstanding interest in whether PMR on its own raises cardiovascular risk. Chronic systemic inflammation is a known driver of atherosclerosis in other rheumatic diseases, so the question is reasonable. The answer, based on current evidence, is not entirely settled. A systematic review found some evidence suggesting PMR may be linked to increased vascular risk, though the authors noted that further studies were needed to pin down how large the risk actually is.⁹

However, a large population-based study reached a more reassuring conclusion, finding that the presence of PMR was not associated with an increased risk of cardiovascular or cerebrovascular diseases regardless of how long the patient had PMR.¹⁰ Similarly, when researchers specifically examined aortic complications like aneurysm and dissection, patients with PMR alone had a risk comparable to the general population. Only patients with GCA showed a significantly elevated rate of aortic events.¹¹ Overall mortality in PMR patients also appears to be similar to the general population, though GCA patients with aortic inflammatory aneurysms face higher mortality.⁷

So the honest picture is nuanced. PMR by itself probably does not dramatically increase your risk of heart attack or stroke, and it does not appear to shorten life expectancy on its own. But the possibility of hidden GCA changes the calculation, because GCA absolutely does carry serious vascular risks. Leaving PMR untreated means leaving any coexisting arterial inflammation untreated too.

Frailty, Muscle Loss, and the Downward Spiral

One of the most underappreciated consequences of untreated PMR is the physical decline that compounds over months. Pain and stiffness keep people sedentary, and prolonged inactivity in older adults causes muscle wasting surprisingly fast. A study tracking physical function and body composition over the first two years of PMR found that about 71% of PMR patients met criteria for pre-frailty at their initial visit, compared to about 34% of age-matched controls. That is roughly seven and a half times the odds of being pre-frail.¹²

Even with treatment, the frailty picture improved only modestly. At follow-up, about 61% of PMR patients were still pre-frail and roughly 6% had become fully frail, a state no controls reached. Women with PMR experienced a significant decline in walking speed over time, losing ground compared to controls at a rate that has real-world implications for independence and fall risk.¹² Separate research found that frail PMR patients had higher inflammatory markers at diagnosis, worse physical function, and more pain than those who were not yet frail.¹³

The implication is that every week of uncontrolled inflammation and immobility pushes a person further down a path that becomes harder to reverse. Muscle strength lost in your seventies does not come back as easily as it did at forty. Early and effective treatment offers the best chance of preserving the physical function you still have.

Sleep Disruption and Relentless Fatigue

Pain alone is enough to ruin sleep, but PMR seems to attack sleep quality and energy levels in ways that go beyond what the pain would predict. Research comparing PMR patients to age-matched controls found that about 77% of PMR patients reported poor sleep quality at the time of diagnosis, and this worsened to 84% at follow-up, compared to 56% of controls at both time points. Severe fatigue affected about 36% of PMR patients at diagnosis and 35% at follow-up, while only 3% of controls reported the same level of exhaustion.¹⁴

The persistence of fatigue and poor sleep even at follow-up, when most patients are on treatment, is striking. It suggests that these symptoms are partly driven by the inflammatory process itself and do not fully resolve even when pain improves. For people who are not treated at all, the fatigue is likely worse and more unrelenting. Chronic sleep deprivation in older adults feeds into cognitive decline, mood disorders, and immune dysfunction, creating yet another layer of harm on top of the disease itself.

When PMR Turns Out to Be Something Else

An important wrinkle in the “what if you don’t treat it” question is that what looks like PMR is not always PMR. The condition has no definitive diagnostic test; it is identified by a combination of symptoms, age, blood work, and response to treatment. That treatment response is itself a diagnostic clue: PMR typically improves dramatically within days of starting low-dose corticosteroids. When it does not, doctors start looking for other explanations.

One observational study that followed PMR patients managed without steroids found that a large majority eventually developed joint inflammation consistent with rheumatoid arthritis. In about 77% of the cohort, a definitive diagnosis of RA could be made on average eight and a half months after the initial PMR symptoms appeared.² That study had a specific methodology that may have enriched for RA cases, but the finding reinforces the point that PMR is sometimes a precursor or early presentation of another disease.

More ominously, PMR-like symptoms can occasionally be a paraneoplastic syndrome, meaning they are caused by an underlying cancer. When atypical features are present, such as asymmetric symptoms, poor steroid response, or unusual blood work, searching for an occult malignancy becomes important.¹⁵ Avoiding medical evaluation and treatment for PMR-like symptoms means potentially missing a cancer diagnosis or an autoimmune disease that needs different and more aggressive therapy.

How Quickly Treatment Actually Works

One reason leaving PMR untreated is particularly frustrating from a medical standpoint is that treatment works remarkably well and remarkably fast. Low-dose corticosteroids, typically prednisone at 10 to 20 mg per day, produce near-complete symptom relief in most patients within days.¹⁶ In one study, about 78% of patients responded to 12.5 mg of prednisone within a month, and the average time from starting treatment to clinical remission was less than a week.¹⁷

Few conditions in rheumatology respond this quickly and reliably to treatment. The speed of response is so characteristic that it helps clinicians confirm the diagnosis. People who go from being unable to raise their arms above their shoulders to feeling nearly normal within three or four days often describe it as miraculous, and it is easy to understand why doctors find it frustrating when patients remain untreated for months.

The catch, of course, is that PMR usually requires a long and careful steroid taper, often spanning one to two years, and steroid side effects accumulate with time. That long-term steroid burden has driven significant interest in alternatives.

Newer Treatments That Reduce Steroid Exposure

For patients who relapse every time steroids are tapered, or who develop intolerable steroid side effects, biologic medications targeting the interleukin-6 pathway have shown genuine promise. Tocilizumab, which blocks the interleukin-6 receptor, significantly reduced relapse rates compared to placebo in pooled analyses of clinical trials. The drug also substantially lowered the total amount of steroids patients needed over the course of treatment.¹⁸ In one trial, about 63% of tocilizumab-treated patients achieved steroid-free remission by week 16, compared to about 12% on placebo.¹⁹

Sarilumab, another interleukin-6 blocker, showed similar benefits in a trial published in the New England Journal of Medicine. About 28% of sarilumab-treated patients achieved sustained remission at one year versus 10% on placebo, and the total steroid dose over a year was cut by more than half in the sarilumab group.²⁰ These biologics do not replace steroids for most patients, but they offer a meaningful safety net for the substantial minority who cannot taper steroids successfully. Their existence makes the argument for leaving PMR entirely untreated even weaker: even if you want to avoid long-term steroids, there are now options that can help reduce that exposure rather than forcing a choice between steroids and nothing.

Hospitalization and the Cost of Delayed Diagnosis

People who present to the healthcare system later in the course of PMR, or who arrive with more severe inflammation, are more likely to end up hospitalized. A study from a fast-track outpatient clinic found that hospitalized PMR patients had a significantly higher average C-reactive protein at diagnosis and a shorter duration of symptoms before seeking care, suggesting they arrived in a more acute and alarming inflammatory state.²¹ Rapid-access outpatient pathways reduced hospitalization rates, which points to a practical takeaway: getting seen quickly by someone who can diagnose and treat PMR prevents the escalation that leads to emergency department visits and inpatient stays.

Hospitalization for what is essentially a treatable outpatient condition exposes older adults to risks like hospital-acquired infections, deconditioning from bed rest, and confusion in unfamiliar settings. It also costs the healthcare system substantially more than an office visit and a prescription. For the patient, it often means days of additional disability that could have been avoided with a timely diagnosis and a simple course of low-dose steroids.